Editas Medicine Inc
NASDAQ:EDIT
Editas Medicine Inc
Total Other Income
Editas Medicine Inc
Total Other Income Peer Comparison
Competitive Total Other Income Analysis
Latest Figures & CAGR of Competitors
Company | Total Other Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Editas Medicine Inc
NASDAQ:EDIT
|
Total Other Income
-$1.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Total Other Income
-$4.7B
|
CAGR 3-Years
6%
|
CAGR 5-Years
-204%
|
CAGR 10-Years
N/A
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Other Income
$252m
|
CAGR 3-Years
22%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Other Income
$2.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Other Income
-$15.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-61%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Other Income
-$20m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-58%
|
See Also
What is Editas Medicine Inc's Total Other Income?
Total Other Income
-1.6m
USD
Based on the financial report for Dec 31, 2023, Editas Medicine Inc's Total Other Income amounts to -1.6m USD.